233 related articles for article (PubMed ID: 36626311)
1. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.
Asempa TE; Kois AK; Gill CM; Nicolau DP
J Antimicrob Chemother; 2023 Mar; 78(3):636-645. PubMed ID: 36626311
[TBL] [Abstract][Full Text] [Related]
2. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.
Asempa TE; Kois AK; Gill CM; Nicolau DP
J Antimicrob Chemother; 2022 Sep; 77(10):2622-2631. PubMed ID: 35325165
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
[TBL] [Abstract][Full Text] [Related]
4. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Lee SY; Gill CM; Nicolau DP;
J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
[TBL] [Abstract][Full Text] [Related]
7. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
[TBL] [Abstract][Full Text] [Related]
8. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
Sader HS; Mendes RE; Duncan L; Kimbrough JH; Carvalhaes CG; Castanheira M
Diagn Microbiol Infect Dis; 2023 Jun; 106(2):115945. PubMed ID: 37060707
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
13. Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in
Sadek M; Bosch Duran J; Poirel L; Nordmann P
Antimicrob Agents Chemother; 2023 May; 67(5):e0007823. PubMed ID: 37039645
[TBL] [Abstract][Full Text] [Related]
14. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
Ruiz VH; Gill CM; Nicolau DP
J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
Nordmann P; Bouvier M; Poirel L
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1145-1152. PubMed ID: 37566365
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
[TBL] [Abstract][Full Text] [Related]
19. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
